pentobarbital will lower the extent or impact of artemether/lumefantrine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Keep away from or Use Alternate Drug. Coadministration with potent CYP3A4 inducers may lead to lessened serum concentrations and loss of antimalarial efficacy
pentobarbital will lessen the level or result of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will lessen the level or influence of alfuzosin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unknown.
Reserve concomitant prescribing of such drugs in clients for whom other cure options are inadequate. Restrict dosages and durations to your minimum needed. Observe intently for signs of respiratory depression and sedation.
pentobarbital will reduce the level or effect of carbamazepine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
pentobarbital raises toxicity of ifosfamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. CYP3A4 inducers could increase the metabolism of ifosfamide to its Energetic alkylating metabolites.
pentobarbital will read more reduce the level or influence of sufentanil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unfamiliar.
Contraindicated (one)pentobarbital will reduce the extent or effect of lumacaftor/ivacaftor by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital decreases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Stay away from Until the coadministration outweighs the probable danger of ponatinib underexposure; check for signs of diminished efficacy.
With therapeutic doses of TCAs, barbiturates maximize metabolism and reduce blood concentrations of TCAs.
pentobarbital will reduce the level or effect of tamoxifen by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
Observe Intently (one)pentobarbital will lower the level or impact of glecaprevir/pibrentasvir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Training warning when administered to clients with acute or Serious agony; could lead to paradoxical excitement or essential indicators may be masked
Withdrawal indicators arise in infants born to moms who obtain barbiturates all through the previous trimester of pregnancy